ClinVar Miner

Submissions for variant NM_003060.4(SLC22A5):c.1463G>A (p.Arg488His) (rs28383481)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000426334 SCV000111946 pathogenic not provided 2015-07-30 criteria provided, single submitter clinical testing
GeneDx RCV000426334 SCV000514640 pathogenic not provided 2017-05-25 criteria provided, single submitter clinical testing The A142S and R488H variants in the SLC22A5 gene have been reported previously in association with systemic primary carnitine deficiency (CDSP) in patients who harbored A142S and R488H on the same SLC22A5 allele (in cis) with a third variant on the opposite allele (Amat di San Filippo et al., 2006, SLC22A5 Mutation database, www.arup.utah.edu; Mazzini et al. 2011). While the A142S variant was not observed with any significant frequency in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, the R488H variant was observed with a frequency of 0.5%, 45/8600 alleles, in individuals of European American ancestry. When A142S and R488H were expressed individually in CHO cells, neither variant reduced carnitine transport (Amat di San Filippo et al., 2006). However, when A142S and R488H were present on the same allele, expression in CHO cells showed significantly impaired carnitine transport, indicating that A142S and R488H need to be present on the same SLC22A5 allele in order to impair function (Amat di San Filippo et al., 2006). Therefore when the R488H missense change is present without a second variant on the same SLC22A5 allele, it is not expected to be a pathogenic variant.
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology RCV000022386 SCV000584115 pathogenic Renal carnitine transport defect 2013-10-21 criteria provided, single submitter research
Invitae RCV000022386 SCV000632535 likely benign Renal carnitine transport defect 2019-12-31 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000426334 SCV000886114 benign not provided 2018-01-31 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000826038 SCV000967529 uncertain significance not specified 2018-09-17 criteria provided, single submitter clinical testing Variant classified as Uncertain Significance - Favor Benign. The p.Arg488His var iant in SLC22A5 has been reported in the compound heterozgous state in at least 5 individuals with primary carnitine deficiency (di San Filippo 2006, Mazzini 20 11, Rose 2012, Frigeni 2017, Thompson 2018); however in all of these individuals a second variant (p.Ala142Ser) was identified on the same copy of the SLC22A5 g ene (in cis). Functional studies indicate that p.Arg488His does not significantl y impact carnitine transport alone, and must occur in cis with p.Ala142Ser to im pact protein function (di San Filippo 2006). However, these types of assays may not accurately represent biological function. The p.Arg488His variant has been i dentified in 0.47% (598/126640) of European chromosomes and 0.32% (884/277154) o f total chromosomes by the Genome Aggregation Database, including 6 homozygotes (gnomAD, http://gnomad.broadinstitute.org). It is also present in ClinVar with c onfliciting interpretations of pathogenicity (Variation ID# 38794). Computationa l prediction tools and conservation analysis do not provide strong support for o r against an impact the protein. Finally, another variant at the same position ( p.Arg488Cys) has been identified in the homozygous state in one individual with primary carnitine deficiency (Schimmenti 2007). In summary, while the clinical s ignificance of this variant is uncertain, these data suggest that, in the absenc e of p.Ala142Ser, the p.Arg488His variant is unlikely to be disease causing. AMC G/AMP criteria applied: PS4_Supporting.
Mendelics RCV000022386 SCV001136973 likely pathogenic Renal carnitine transport defect 2019-05-28 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000022386 SCV001313204 uncertain significance Renal carnitine transport defect 2017-04-27 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Research and Development, ARUP Laboratories RCV000022386 SCV000043071 not provided Renal carnitine transport defect no assertion provided clinical testing
Counsyl RCV000022386 SCV001132485 uncertain significance Renal carnitine transport defect 2017-09-22 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.